THE SCIENTIFIC DISCOURSE ON PHARMACOLOGY AND BIOINFORMATIC ANALYSIS IN MODERN DRUG DESIGN: FROM TARGET DISCOVERY TO TRANSLATIONAL OPTIMIZATION THROUGH INTEGRATED MOLECULAR, COMPUTATIONAL, STRUCTURAL, SYSTEMS AND PRECISION MEDICINE APPROACHES
DOI:
https://doi.org/10.52340/spectri.2026.13.01.06Keywords:
Pharmacology, bioinformatics, drug design, structure-based drug discovery, systems pharmacology, molecular dynamics, multi-omics, pharmacokinetic-pharmacodynamic modelingAbstract
Drug discovery has evolved from a largely empirical discipline into a knowledge-intensive enterprise that depends on the integration of pharmacology, structural biology, computational chemistry, and bioinformatics. Modern pharmacotherapeutic design is no longer satisfied by the demonstration that a molecule binds a macromolecular target. Instead, a candidate must be considered within a broader context that includes disease mechanism, network position of the target, tissue expression, structural tractability, off-target liabilities, pharmacokinetic behavior, and the probability of translation from preclinical systems to humans. Bioinformatic analysis has become central to this process because it enables the organization and interpretation of genomic, transcriptomic, proteomic, metabolomic, phenotypic, and chemical data at a scale that cannot be managed by traditional reductionist workflows alone. Pharmacology remains equally indispensable because the relevance of computational outputs depends on mechanistic interpretation, exposure-response understanding, and a realistic view of efficacy and safety in complex biological systems. This review examines how pharmacology and bioinformatic analysis jointly inform contemporary drug design across the discovery pipeline. It discusses target identification and validation, structural bioinformatics, structure-based and ligand-based design, network pharmacology, multi-omics analysis, ADMET prediction, and pharmacokinetic-pharmacodynamic modeling. It also addresses the increasing role of machine learning, not as a replacement for experimental science, but as a tool for prioritization, pattern recognition, and iterative decision support. Particular emphasis is placed on the limitations of current approaches, including database incompleteness, bias in training sets, uncertain biological annotation, and the common error of overinterpreting docking scores or predictive probabilities as proof of therapeutic success. The central argument is that the most reliable drug design strategies emerge when computational breadth is combined with pharmacological depth. In that integrative framework, bioinformatics helps define what should be tested, while pharmacology determines what the resulting signals actually mean for drug action, safety, and translation.
Downloads
References
1. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010;9(3):203-214.
2. Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. Br J Pharmacol. 2011;162(6):1239-1249.
3. Waring MJ, Arrowsmith J, Leach AR, Leeson PD, Mandrell S, Owen RM, et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov. 2015;14(7):475-486.
4. Macarron R, Banks MN, Bojanic D, Burns DJ, Cirovic DA, Garyantes T, et al. Impact of high-throughput screening in biomedical research. Nat Rev Drug Discov. 2011;10(3):188-195.
5. Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074-D1082.
6. Gaulton A, Hersey A, Nowotka M, Bento AP, Chambers J, Mendez D, et al. The ChEMBL database in 2017. Nucleic Acids Res. 2017;45(D1):D945-D954.
7. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607-D613.
8. Varadi M, Anyango S, Deshpande M, Nair S, Natassia C, Yordanova G, et al. AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. 2022;50(D1):D439-D444.
9. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583-589.
10. Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov. 2004;3(11):935-949.
11. Lionta E, Spyrou G, K Vassilatis D, Cournia Z. Structure-based virtual screening for drug discovery: principles, applications and recent advances. Curr Top Med Chem. 2014;14(16):1923-1938.
12. Hollingsworth SA, Dror RO. Molecular dynamics simulation for all. Neuron. 2018;99(6):1129-1143.
13. Van de Waterbeemd H, Gifford E. ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov. 2003;2(3):192-204.
14. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1-3):3-26.
15. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45(12):2615-2623.
16. Walters WP, Murcko MA. Prediction of 'drug-likeness'. Adv Drug Deliv Rev. 2002;54(3):255-271.
17. Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem. 2010;53(7):2719-2740.
18. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-15550.
19. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929-1935.
20. Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database Hallmark Gene Set Collection. Cell Syst. 2015;1(6):417-425.
21. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498-2504.
22. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682-690.
23. Csermely P, Korcsmaros T, Kiss HJM, London G, Nussinov R. Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review. Pharmacol Ther. 2013;138(3):333-408.
24. Mestres J, Gregori-Puigjane E, Valverde S, Sole RV. Data completeness—the Achilles heel of drug-target networks. Nat Biotechnol. 2008;26(9):983-984.
25. Danhof M, de Jongh J, De Lange ECM, Della Pasqua O, Ploeger BA, Voskuyl RA. Mechanism-based pharmacokinetic-pharmacodynamic modeling in translational drug research. Trends Pharmacol Sci. 2007;28(3):122-129.
26. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28(6):507-532.
27. Smith DA, Di L, Kerns EH. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov. 2010;9(12):929-939.
28. Ferreira LG, dos Santos RN, Oliva G, Andricopulo AD. Molecular docking and structure-based drug design strategies. Molecules. 2015;20(7):13384-13421.
29. Gorgulla C, Boeszoermenyi A, Wang ZF, Fischer PD, Coote PW, Das KM, et al. An open-source drug discovery platform enables ultra-large virtual screens. Nature. 2020;580(7805):663-668.
30. Maia EHB, Assis LC, de Oliveira TA, da Silva AM Jr, Taranto AG. Structure-based virtual screening: from classical to artificial intelligence. Front Chem. 2020;8:343.
31. Schneider G. Automating drug discovery. Nat Rev Drug Discov. 2018;17(2):97-113.
32. Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. Drug Discov Today. 2018;23(6):1241-1250.
33. Ekins S, Puhl AC, Zorn KM, Lane TR, Russo DP, Klein JJ, et al. Exploiting machine learning for end-to-end drug discovery and development. Nat Mater. 2019;18(5):435-441.
34. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463-477.
35. Stokes JM, Yang K, Swanson K, Jin W, Cubillos-Ruiz A, Donghia NM, et al. A deep learning approach to antibiotic discovery. Cell. 2020;180(4):688-702.e13.
36. Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, et al. Defining a Cancer Dependency Map. Cell. 2017;170(3):564-576.e16.
37. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18(1):83.
38. Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms. Nat Rev Mol Cell Biol. 2016;17(7):451-459.
39. Scannell JW, Bosley J. When quality beats quantity: decision theory, drug discovery, and the reproducibility crisis. PLoS One. 2016;11(2):e0147215.
40. Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096.
41. Chikava M, Tsintsadze T, Mishelashvili K, Sulashvili N. Modern theories of homeopathic Nanopharmacology. Nano Studies. 2014 Sep;(3):107-110.
42. Arabuli L, Sulashvili N, Kvizhinadze N. Synthesis and in vitro Cytotoxicity Testing of New Cy-clen-Peptide Conjugations. Caucasus Journal of Health Sciences and Public Health. 2016 Jun;1(Suppl 1):105-109.
43. Arabuli L, Jezek R, Macek T, Lovecka P, Nikoleishvili E, Sulashvili N, et al. Solid-Phase Synthe-sis and In Vitro Cytotoxicity of New Peptide Functionalized Cyclencarboxymethylen and L-DOPA Hybrids. Medicinal Chemistry (Los Angeles). 2017;7(12):398-407.
44. Arabuli L, Sulashvili N, Kvizhinadze N. New Derivatives of 10-chloro-5,10-dihydrophenarsazine with Potential Biological Activity. Caucasus Journal of Health Sciences and Public Health. 2017 Jun;1(Suppl 2):113.
45. Gakhutishvili M, Brostow W, Sulashvili N, Pirtskhalava T. Antibacterial Arsenic Doped Polymer Composites in Healthcare and Hospitals. In: Abstracts of Seventh (7th) International Caucasian Symposium on Polymers and Advanced Materials. Tbilisi; 2021 Jul 27-30. p. 32.
46. Avagimyan A, Kajaia A, Gabunia L, Ghambashidze K, Sulashvili N, Ratiani L, et al. Urotensin-II As a Promising Key-Point of Cardiovascular Disturbances Sequel. Current Problems in Cardiolo-gy. 2021 Nov 27;101074.
47. Sulashvili N, Gorgaslidze N, Beglaryan M. The Scientific Achievements of the Problems and Per-spectives of Coronavirus Vaccine Enhancement for Prevention and Prophylaxis of the COVID-19 Diseases. In: Materials of the VII International Scientific-Practical Conference "Social Pharmacy: State, Problems and Prospects". Kharkiv: National Pharmaceutical University of Ukraine; 2021 Sep 23-24. p. 117-149.
48. Sulashvili N, Beglaryan M, Gorgaslidze N. The Scientific Discussion of the Pharmacists' State Problems and Perspectives of Regular Judging by the Position of Patients in Georgia. In: Materials of the VII International Scientific-Practical Conference "Social Pharmacy: State, Problems and Prospects". Kharkiv: National Pharmaceutical University of Ukraine; 2021 Sep 23-24. p. 81-106.
49. Sulashvili N, Gorgaslidze N, Beglaryan M. The Scientific Debates of Peculiarities of Problems, Perspectives and Role of the Clinical Pharmacists Worldwide in General in the XXI Century. In: Materials of the VII International Scientific-Practical Conference "Social Pharmacy: State, Prob-lems and Prospects". Kharkiv: National Pharmaceutical University of Ukraine; 2021 Sep 23-24. p. 284-317.
50. Sulashvili N, Gorgaslidze N, Beglaryan M. The Features of Problems and Prospects Clinical Pharmacist in General and Aspects of Pharmaceutical Care in Different Directions of Action of Pharmaceutics and Public Health. In: Materials of VII International Scientific and Practical con-ferences "Technological and Biopharmaceutical Aspects of Drugs Developing with Different Ori-entation of Action". Kharkiv: National Pharmaceutical University of Ukraine; 2022 Nov 24-25. p. 119-145.
51. Sulashvili N, Gorgaslidze N, Beglaryan M, Chichoyan N, Gabunia L, Zarnadze I, et al. Scientific Talks of the Features of the Pharmacist' Profession, Essential Role, Achievements, Problems, As-pects and Higher Pharmaceutical Educational Advancement Issue Perspectives in the Context of Patients Safety Locally and Globally in XXI Century. Bulletin of the Medical Institute After Mehrabyan. 2021;11:37-68.
52. Sulashvili N, Alavidze N, Kvizhinadze N, Okropiridze T. The Features of Pharmacists' Profes-sional Issue Approaches, Ensuring, Aspirations and Requirements According the Mind of Patients in Georgia. In: Materials of the international scientific and practical conference "Current Issues of Pharmacology, Clinical Pharmacology and Clinical Pharmacy". Kharkiv: National Pharmaceutical University of Ukraine; 2022 Oct 27-28. p. 20-36.
53. Sulashvili N, Beglaryan M, Gorgaslidze N. The Scientific Discussion of Inclination, Achieve-ments, Tenacities, Innovations, Aspiration and Perspectives of Pharmacists' Profession in Georgia and Globally. Bulletin of the Medical College After Mehrabyan. 2022;13:31-54.
54. Sulashvili N, Beglaryan M, Gorgaslidze N. Scientific Talks of the Features of the Pharmacist' Pro-fession, Essential Role, Achievements, Problems, Aspects and Higher Pharmaceutical Educational Advancement Issue Perspectives in the Context of Patients Safety Locally and Globally in XXI Century. In: Proceedings of the III International Scientific and Practical Conference "Modern Pharmacy -- Science and Practice". Kutaisi: Akaki Tsereteli State University; 2023 Sep 5-30. p. 183-204.
55. Sulashvili N, Beglaryan M, Gorgaslidze N. The Scientific Talks of the Manifestation of Pharma-cists New Engagement, Purpose, Involvement, Challenges, Professional Development, Perspec-tives and Modern Trends Implementation in Pharmacy Education, According New Impediments in XXI Century in the Domestic and International Context in General. In: Materials of the III In-ternational Scientific and Practical Conference, Dedicated to the 40th Anniversary of the Founda-tion of the Department of Organization, Economics and Management of Pharmacy. Kharkiv: Na-tional Pharmacy University of Ukraine; 2024 Oct 23-24. p. 370-388.
56. Arabuli L, Nikoleishvili E, Sulashvili N. Solid-Phase Synthesis of Bifunctional Macrocyclic Poly-amines Targeting Neurodegenerative diseases. In: International scientific conference "Future Technologies and Quality of Life". Batumi: TSMU; 2017 Sep 29-Oct 1. p. 3.
57. Arabuli L, Sulashvili N, Kvizhinadze N. New Derivatives of 10-chloro-5,10-dihydrophenarsazine with Potential Biological Activity. In: International Science and Innovation Festival 2017. Tbilisi: TSMU; 2017 Sep. p. 12-13.
58. Sulashvili N, Gorgaslidze N, Beglaryan M. The Scientific Discussion of Features, Challenges, Per-spectives of Pharmacists' and Professional Issue Aspects in Different Directions of Action in Pharmacy, Medicine and Public Health in Georgia. In: Materials of VII International Scientific and Practical conferences "Technological and Biopharmaceutical Aspects of Drugs Developing with Different Orientation of Action". Kharkiv: National Pharmaceutical University of Ukraine; 2022 Nov 24-25. p. 231-260.
59. Sulashvili N, Gorgaslidze N, Beglaryan M, Lobjanidze T, Chichoyan N, Gabunia L, et al. The Manifestation of the Key Issue Aspects of Pharmacists' Professional Aspiration, Development, Perfection and Social Pharmacy State Problems, Prospects, Pharmaceutical Education and Man-agement Features in General. In: Proceedings of the III International Scientific and Practical Con-ference "Fundamental and Applied Research in the Field of Pharmaceutical Technology". Kharkiv: National Pharmaceutical University of Ukraine; 2023 Nov 24. p. 166-199.
60. Sulashvili N, Beglaryan M, Gorgaslidze N. The Key Issue of Manifestation of Modern Aspects of Achievements of Pharmacists Profession, Pharmaceutical Education, Science and Organizational Aspects of Pharmaceutics in Georgia. In: Materials of II Scientific and Practical International Conference On The Topic "Modern Aspects of Achievements Fundamental and Applied Medical and Biological Areas Medical and Pharmaceutical Education and Science". Kharkiv: Kharkiv Na-tional Medical University; 2023 Nov 17. p. 271-288.
61. Rekhviashvili D, Chakhunashvili G, Megrelishvili N, Taboridze I. Diabetic Dyslipidemia in Geor-gian Children with Type 1 Diabetes. Translational and Clinical Medicine-Georgian Medical Jour-nal. 2026 Jun 30;11(2):41
62. Rekhviashvili D, Chakhunashvili G, Chkhaidze M, Abdushelishvili N, Arveladze G, Kevlishvili S, Taboridze I. ASSESSMENT OF THE LIPID SPECTRUM IN GEORGIAN CHILDREN WITH TYPE 1 DIABETES MELLITUS. Georgian Medical News. 2026 Apr 1(373):30-5.
63. Shervashidze T, Kvanchakhadze R, Shervashidze M, Abuladze D, Jashi L, Taboridze I. Metabolic and Cardiometabolic Changes After Sleeve Gastrectomy in a Patient With Type 1 Diabetes and Morbid Obesity: A CARE-Compliant Case Report. The Georgian Medical Journal. 2026 Mar 20;1(1):185-98.
64. Dundua K, Taboridze I, Kvanchakhadze R, Abesadze I, Jashi L. CORRELATIONS BETWEEN HOMOCYSTEINE AND VITAMIN B12 IN TYPE 2 DIABETES TREATED WITH MET-FORMIN. Georgian medical news. 2026 Mar(372):6-12.
65. Gujejiani L, Latsuzbaia K, Taboridze I. Prinzmetal Angina: A Case of Recurrent Ventricular Fi-brillation. Eur Sci J. 2026;22(12).
66. Kokhreidze A, Saginadze L, Kvanchaxadze R, Gordeladze M, Janjgava S, Taboridze I. THE HIDDEN LINK: HOW VITAMIN D AND ZINC INFLUENCE GROWTH AND MENTAL HEALTH IN CHILDREN. Georgian Medical News. 2025 Mar 1(360):13-9.
67. Dundua K, Taboridze I, Kvanchakhadze R. Evaluation of Vitamin B12 and Homocysteine Status in Patients with Type 2 Diabetes Mellitus without Metformin Therapy. Scientific Journal „Spectri “. 2025;12(2).
68. Shervashidze T, Kvanchakhadze R, Abuladze D, Jashi L, Shervashidze M, Sakvarelidze I, Makha-radze M, Taboridze I. THE IMPACT OF BARIATRIC SURGERY ON TYPE 2 DIABETES MELLITUS REMISSION IN THE GEORGIAN POPULATION. Georgian Medical News. 2025 Jan 1(358):106-12.
69. Arabidze K, Gogokhia I, Sokhadze K, Kintsurashvili N, Tsiklauri M, Gogichaishvili T, Tabordze I. THE EVALUATION OF THE RISK OF COMPLICATIONS DURING MULTIMODAL AND OPIOID ANESTHESIA IN BARIATRIC SURGERY AND ABDOMINOPLASTY. Georgian Medical News. 2023 Dec 1(345):67-71.
70. Kacharava T, Giorgadze E, Janjgava S, Lomtadze N, Taboridze I. Correlation between vitamin B12 deficiency and autoimmune thyroid diseases. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders). 2023 Jan 1;23(1):86-94.
71. Lomtadze N, Giorgadze E, Janjgava S, Kacharava T, Taboridze I. The relationship between insulin resistance and thyroid volume in Georgia. Endocrine, Metabolic & Immune Disorders-Drug Tar-gets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders). 2023 Sep 1;23(10):1318-25.
72. Chigogidze M, Pagava Z, Taboridze I, Lomia N, Saatashvili G, Sharashidze N. ASSESSMENT OF CORONARY COLLATERAL CIRCULATION PREDICTORS AMONG PATIENTS WITH ACUTE CORONARY SYNDROME IN POPULATION GEORGIA. Georgian Medical News. 2023 Jan 1(334):57-64.
73. Gogishvili G, Petriashvili S, Nanobashvili N, Megrelishvili N, Taboridze I. Evaluation of Diagnos-tic Value of Non-HDL Lipoproteins in Georgian Population Under 45 Years of Age with Coro-nary Heart Disease. Sci J Spectri. 2021;5:15-19.
74. Arabidze K, Gogokhia I, Lebanidze N, Taboridze I. POSTOPERATIVE PAIN AND MULTI-MODAL ANESTHESIA IN ABDOMINAL PLASTIC AND BARIATRIC SURGERY. Int J Innov Med Healthc. 2023;4(1):23-28.
75. Diasamidze E, Gvenetadze T, Antadze G, Taboridze I, Giorgobiani G. THE IMPACT OF ANE-MIA ON THE DEVELOPMENT OF INCISIONAL HERNIA, PROSPECTIVE STUDY. Georgian Medical News. 2025 Dec 1(369):63-7.
76. Kokhreidze A, Saginadze L, Kvanchaxadze R, Gordeladze M, Janjgava S, Taboridze I, et al. MI-CRONUTRIENTS AND THE MIND: HOW ZINC AND VITAMIN D AFFECT CHILD DE-VELOPMENT. Proc Int Res Educ Train Cent. 2025;35(2).
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
